Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Jasper Therapeutics Inc (JSPR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
07/01/2025: JSPR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
11 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $48.22
1 Year Target Price $48.22
| 7 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 77.1% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 07/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 83.37M USD | Price to earnings Ratio - | 1Y Target Price 48.22 |
Price to earnings Ratio - | 1Y Target Price 48.22 | ||
Volume (30-day avg) 11 | Beta 2.73 | 52 Weeks Range 3.13 - 26.05 | Updated Date 07/1/2025 |
52 Weeks Range 3.13 - 26.05 | Updated Date 07/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -5.27 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -56.5% | Return on Equity (TTM) -101.34% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37313998 | Price to Sales(TTM) - |
Enterprise Value 37313998 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.42 | Shares Outstanding 15022100 | Shares Floating 9908441 |
Shares Outstanding 15022100 | Shares Floating 9908441 | ||
Percent Insiders 1.27 | Percent Institutions 87.97 |
Analyst Ratings
Rating 3 | Target Price 48.22 | Buy 4 | Strong Buy 7 |
Buy 4 | Strong Buy 7 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Jasper Therapeutics Inc
Company Overview
History and Background
Jasper Therapeutics, Inc. is a biotechnology company focused on the development and commercialization of engineered hematopoietic stem cell therapies. Founded in 2016, the company focuses on addressing unmet medical needs in patients with hematologic diseases, cancer, and autoimmune diseases. The company went public through a SPAC merger in 2022.
Core Business Areas
- Hematopoietic Stem Cell Therapies: Developing and commercializing engineered hematopoietic stem cell therapies, primarily focusing on conditioning agents and stem cell engineering.
- Briquilimab: Briquilimab is Jasper Therapeutics' lead product candidate, a first-in-class anti-c-KIT antibody being developed as a conditioning agent for hematopoietic stem cell transplantation.
Leadership and Structure
The company is led by a management team with experience in biopharmaceutical development and commercialization. The organizational structure includes research and development, clinical operations, and commercial functions.
Top Products and Market Share
Key Offerings
- Briquilimab: Briquilimab is a monoclonal antibody targeting the c-KIT receptor on hematopoietic stem cells. It is being developed as a conditioning agent for hematopoietic stem cell transplantation, aiming to replace or reduce the need for traditional chemotherapy or radiation. Market share data for potential future sales is currently unavailable. Competitors include companies developing other conditioning regimens for stem cell transplant, such as those using targeted radiation or novel chemotherapeutic agents.
Market Dynamics
Industry Overview
The hematopoietic stem cell transplantation market is driven by the increasing incidence of hematologic malignancies and autoimmune diseases. The market is competitive, with pharmaceutical companies developing novel conditioning agents and stem cell engineering technologies.
Positioning
Jasper Therapeutics aims to position itself as a leader in the conditioning space with Briquilimab, offering a potentially safer and more effective alternative to traditional conditioning regimens.
Total Addressable Market (TAM)
The TAM for conditioning agents in hematopoietic stem cell transplantation is estimated to be in the billions of dollars annually. Jasper Therapeutics is positioning Briquilimab to capture a significant portion of this market by addressing the limitations of current treatments.
Upturn SWOT Analysis
Strengths
- Novel conditioning agent with potential for improved safety profile
- Targeting a large and growing market
- Experienced management team
Weaknesses
- Reliance on a single lead product candidate
- Clinical trial execution risk
- Limited commercial infrastructure
Opportunities
- Expanding Briquilimab's use to additional indications
- Partnering with other companies to accelerate commercialization
- Developing next-generation stem cell therapies
Threats
- Competition from established conditioning regimens
- Regulatory hurdles and clinical trial failures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- Bayer (BAYRY)
- Novartis (NVS)
- Bristol Myers Squibb (BMY)
Competitive Landscape
Jasper Therapeutics faces competition from established pharmaceutical companies with existing conditioning regimens and novel therapies. Its competitive advantage lies in the potential of Briquilimab to offer a safer and more effective conditioning option.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is pre-revenue.
Future Projections: Future growth depends on the successful development and commercialization of Briquilimab. Analyst estimates vary widely based on the perceived probability of success.
Recent Initiatives: Recent initiatives include advancing Briquilimab through clinical trials and exploring potential partnerships.
Summary
Jasper Therapeutics is a clinical-stage biotech company with a promising lead product, Briquilimab, targeting a significant market need. The company faces risks associated with clinical development and commercialization. Its success depends on demonstrating the safety and efficacy of Briquilimab and securing regulatory approval. The competitive landscape is intense with large pharmaceutical players already with established treatments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company press releases
- SEC filings
- Analyst reports
- ClinicalTrials.gov
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share data is an estimate and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Jasper Therapeutics Inc
Exchange NASDAQ | Headquaters Redwood City, CA, United States | ||
IPO Launch date 2021-09-24 | President, CEO & Director Mr. Ronald A. Martell | ||
Sector Healthcare | Industry Biotechnology | Full time employees 64 | Website https://jaspertx.com |
Full time employees 64 | Website https://jaspertx.com | ||
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases. The company's lead product candidate is briquilimab, a monoclonal antibody designed to block stem cell factor from binding to and signaling through the CD117 receptor on mast and stem cells. It focuses on the development and commercialization of therapeutic agents for patients with various mast cell driven diseases, including chronic spontaneous urticaria, chronic inducible urticaria, and asthma, as well as conditioning agents for stem cell transplant in patients with sickle cell disease, Fanconi anemia, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.